|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu L, Wan S, Li J, Xu Y, Lou X, Sun M and
Wang S: Expression and prognostic value of E2F3 transcription
factor in non-small cell lung cancer. Oncol Lett. 21:4112021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jahanzeb M, Lin HM, Pan X, Yin Y, Baumann
P and Langer CJ: Immunotherapy treatment patterns and outcomes
among ALK-positive patients with non-small-cell lung cancer. Clin
Lung Cancer. 22:49–57. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Borghaei H, Gettinger S, Vokes EE, Chow
LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O,
Frontera OA, Chiari R, et al: Five-year outcomes from the
randomized, phase III trials checkmate 017 and 057: Nivolumab
versus docetaxel in previously treated non-small-cell lung cancer.
J Clin Oncol. 39:723–733. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qu J, Mei Q, Liu L, Cheng T, Wang P, Chen
L and Zhou J: The progress and challenge of anti-PD-1/PD-L1
immunotherapy in treating non-small cell lung cancer. Ther Adv Med
Oncol. 13:17588359219929682021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu L, Bai H, Wang C, Seery S, Wang Z,
Duan J, Li S, Xue P, Wang G, Sun Y, et al: Efficacy and safety of
first-line immunotherapy combinations for advanced NSCLC: A
systematic review and network meta-analysis. J Thorac Oncol.
16:1099–1117. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang L, Yang Y, Yu J, Zhang S, Li X, Wu X,
Nie X, Liu W, Zhang P, Li Y, et al: Efficacy and safety of
anti-PD-1/PD-L1 in combination with chemotherapy or not as
first-line treatment for advanced non-small cell lung cancer: A
systematic review and network meta-analysis. Thorac Cancer.
13:322–337. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xue Y, Gao S, Gou J, Yin T, He H, Wang Y,
Zhang Y, Tang X and Wu R: Platinum-based chemotherapy in
combination with PD-1/PD-L1 inhibitors: Preclinical and clinical
studies and mechanism of action. Expert Opin Drug Deliv.
18:187–203. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xia L, Liu Y and Wang Y: PD-1/PD-L1
blockade therapy in advanced non-small-cell lung cancer: Current
status and future directions. Oncologist. 24:S31–S41. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Patil NS, Nabet BY, Müller S, Koeppen H,
Zou W, Giltnane J, Au-Yeung A, Srivats S, Cheng JH, Takahashi C, et
al: Intratumoral plasma cells predict outcomes to PD-L1 blockade in
non-small cell lung cancer. Cancer Cell. 40:289–300.e284. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y,
Lin D, Gao Q, Zhou H, Liao W and Yao H: Association of survival and
immune-related biomarkers with immunotherapy in patients with
non-small cell lung cancer: A meta-analysis and individual
patient-level analysis. JAMA Netw Open. 2:e1968792019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bai X, Wu DH, Ma SC, Wang J, Tang XR, Kang
S, Fu QJ, Cao CH, Luo HS, Chen YH, et al: Development and
validation of a genomic mutation signature to predict response to
PD-1 inhibitors in non-squamous NSCLC: A multicohort study. J
Immunother Cancer. 8:e0003812020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
André T, Shiu KK, Kim TW, Jensen BV,
Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs
P, et al: Pembrolizumab in microsatellite-instability-high advanced
colorectal cancer. N Engl J Med. 383:2207–2218. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Q, Zhou ZW, Lu J, Luo H, Wang SN, Peng
Y, Deng MS, Song GB, Wang JM, Wei X, et al: PD-L1(P146R) is
prognostic and a negative predictor of response to immunotherapy in
gastric cancer. Mol Ther. 30:621–631. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kumagai S, Togashi Y, Kamada T, Sugiyama
E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y,
Matsui S, et al: The PD-1 expression balance between effector and
regulatory T cells predicts the clinical efficacy of PD-1 blockade
therapies. Nat Immunol. 21:1346–1358. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie Q, Chen Z, Xia L, Zhao Q, Yu H and
Yang Z: Correlations of PD-L1 gene polymorphisms with
susceptibility and prognosis in hepatocellular carcinoma in a
Chinese Han population. Gene. 674:188–194. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoshida H, Nomizo T, Ozasa H, Tsuji T,
Funazo T, Yasuda Y, Ajimizu H, Yamazoe M, Kuninaga K, Ogimoto T, et
al: PD-L1 polymorphisms predict survival outcomes in advanced
non-small-cell lung cancer patients treated with PD-1 blockade. Eur
J Cancer. 144:317–325. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nomizo T, Ozasa H, Tsuji T, Funazo T,
Yasuda Y, Yoshida H, Yagi Y, Sakamori Y, Nagai H, Hirai T and Kim
YH: Clinical impact of single nucleotide polymorphism in PD-L1 on
response to nivolumab for advanced non-small-cell lung cancer
patients. Sci Rep. 7:451242017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun X, Xu J, Xie L and Guo W:
Effectiveness and tolerability of anlotinib plus PD-1 inhibitors
for patients with previously treated metastatic soft-tissue
sarcoma. Int J Gen Med. 15:7581–7591. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seymour L, Bogaerts J, Perrone A, Ford R,
Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et
al: iRECIST: Guidelines for response criteria for use in trials
testing immunotherapeutics. Lancet Oncol. 18:e143–e152. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song ZZ, Zhao LF, Zuo J, Fan ZS, Wang L
and Wang YD: Clinical outcomes and safety of apatinib mesylate in
the treatment of advanced non-squamous non-small cell lung cancer
in patients who progressed after standard therapy and analysis of
the KDR gene polymorphism. Onco Targets Ther. 13:603–613. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Su J, Dai B, Yuan W, Wang G, Zhang Z, Li
Z, Liu J and Song J: The influence of PD-L1 genetic variation on
the prognosis of R0 resection colorectal cancer patients received
capecitabine-based adjuvant chemotherapy: A long-term follow-up,
real-world retrospective study. Cancer Chemother Pharmacol.
85:969–978. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Barber RD, Harmer DW, Coleman RA and Clark
BJ: GAPDH as a housekeeping gene: Analysis of GAPDH mRNA expression
in a panel of 72 human tissues. Physiol Genomics. 21:389–395. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang H, Liu Z, Wen H, Guo Y, Xu F, Zhu Q,
Yuan W, Luo R, Lu C, Liu R, et al: Immunosuppressive TREM2(+)
macrophages are associated with undesirable prognosis and responses
to anti-PD-1 immunotherapy in non-small cell lung cancer. Cancer
Immunol Immunother. 71:2511–2522. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yin J, Wu Y, Yang X, Gan L and Xue J:
Checkpoint inhibitor pneumonitis induced by anti-PD-1/PD-L1 therapy
in non-small-cell lung cancer: Occurrence and mechanism. Front
Immunol. 13:8306312022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou C, Wang Y, Zhao J, Chen G, Liu Z, Gu
K, Huang M, He J, Chen J, Ma Z, et al: Efficacy and biomarker
analysis of camrelizumab in combination with apatinib in patients
with advanced nonsquamous NSCLC previously treated with
chemotherapy. Clin Cancer Res. 27:1296–1304. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bie F, Tian H, Sun N, Zang R, Zhang M,
Song P, Liu L, Peng Y, Bai G, Zhou B and Gao S: Research progress
of anti-PD-1/PD-L1 immunotherapy related mechanisms and predictive
biomarkers in NSCLC. Front Oncol. 12:7691242022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu Z, Li T, Hu X, Hao X, Xing P and Li J:
Efficacy and safety profile of combining programmed cell death-1
(PD-1) inhibitors and antiangiogenic targeting agents as subsequent
therapy for advanced or metastatic non-small cell lung cancer
(NSCLC). Thorac Cancer. 12:2360–2368. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu
Y, Ma Z, Wang Z, Cheng Y, Wang J, et al: Tislelizumab versus
docetaxel in patients with previously treated advanced NSCLC
(RATIONALE-303): A phase 3, open-label, randomized controlled
trial. J Thorac Oncol. 18:93–105. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Geng N, Su J, Liu Z, Ding C, Xie S and Hu
W: The influence of KDR genetic variation on the efficacy and
safety of patients with advanced NSCLC receiving first-line
bevacizumab plus chemotherapy regimen. Technol Cancer Res Treat.
20:153303382110194332021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li XP, Zhang WD, Li MJ, Wang J, Lian J and
Zhou HG: Effectiveness and safety of PD-1 inhibitor monotherapy for
elderly patients with advanced non-small cell lung cancer: A
real-world exploratory study. J Oncol. 2022:17102722022.PubMed/NCBI
|
|
36
|
Qiao M, Jiang T, Liu X, Mao S, Zhou F, Li
X, Zhao C, Chen X, Su C, Ren S and Zhou C: Immune checkpoint
inhibitors in EGFR-mutated NSCLC: Dusk or dawn? J Thorac Oncol.
16:1267–1288. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee CK, Man J, Lord S, Cooper W, Links M,
Gebski V, Herbst RS, Gralla RJ, Mok T and Yang JC: Clinical and
molecular characteristics associated with survival among patients
treated with checkpoint inhibitors for advanced non-small cell lung
carcinoma: A systematic review and meta-analysis. JAMA Oncol.
4:210–216. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Masuda K, Horinouchi H, Tanaka M,
Higashiyama R, Shinno Y, Sato J, Matsumoto Y, Okuma Y, Yoshida T,
Goto Y, et al: Efficacy of anti-PD-1 antibodies in NSCLC patients
with an EGFR mutation and high PD-L1 expression. J Cancer Res Clin
Oncol. 147:245–251. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu S, Wu F, Li X, Zhao C, Jia Y, Jia K,
Han R, Qiao M, Li W, Yu J, et al: Patients with short PFS to
EGFR-TKIs predicted better response to subsequent anti-PD-1/PD-L1
based immunotherapy in EGFR common mutation NSCLC. Front Oncol.
11:6399472021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Parakh S, Musafer A, Paessler S, Witkowski
T, Suen C, Tutuka CSA, Carlino MS, Menzies AM, Scolyer RA, Cebon J,
et al: PDCD1 polymorphisms may predict response to anti-PD-1
blockade in patients with metastatic melanoma. Front Immunol.
12:6725212021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Geng N, Ding CM, Liu ZK, Song S and Hu WX:
Influence of VEGFR2 gene polymorphism on the clinical outcomes of
apatinib for patients with chemotherapy-refractory extensive-stage
SCLC: A real-world retrospective study. Int J Clin Oncol.
26:670–683. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Minari R, Bonatti F, Mazzaschi G, Dodi A,
Facchinetti F, Gelsomino F, Cinquegrani G, Squadrilli A, Bordi P,
Buti S, et al: PD-L1 SNPs as biomarkers to define benefit in
patients with advanced NSCLC treated with immune checkpoint
inhibitors. Tumori. 108:47–55. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Enkhbat T, Nishi M, Takasu C, Yoshikawa K,
Jun H, Tokunaga T, Kashihara H, Ishikawa D and Shimada M:
Programmed cell death ligand 1 expression is an independent
prognostic factor in colorectal cancer. Anticancer Res.
38:3367–3373. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhou C, Che G, Zheng X, Qiu J, Xie Z, Cong
Y, Pei X, Zhang H, Sun H and Ma H: Expression and clinical
significance of PD-L1 and c-Myc in non-small cell lung cancer. J
Cancer Res Clin Oncol. 145:2663–2674. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yang Q, Xu Z, Zheng L, Zhang L, You Q and
Sun J: Multimodal detection of PD-L1: Reasonable biomarkers for
immune checkpoint inhibitor. Am J Cancer Res. 8:1689–1696.
2018.PubMed/NCBI
|
|
46
|
Wu Y, Zhao T, Jia Z, Cao D, Cao X, Pan Y,
Zhao D, Zhang B and Jiang J: Polymorphism of the programmed
death-ligand 1 gene is associated with its protein expression and
prognosis in gastric cancer. J Gastroenterol Hepatol. 34:1201–1207.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Song X, Zhong H, Zhou J, Hu X, Zhou Y, Ye
Y, Lu X, Wang J, Ying B and Wang L: Association between
polymorphisms of microRNA-binding sites in integrin genes and
gastric cancer in Chinese Han population. Tumour Biol.
36:2785–2792. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
